Lineage Cell Therapeutics (LCTX) FCF Margin (2010 - 2026)
Lineage Cell Therapeutics (LCTX) reported FCF Margin of 472.35% for Q1 2026, down 14059.0% on a YoY basis from N/an in Q1 2025, and down 480.7% quarter-over-quarter from 81.34% in Q4 2025.
Lineage Cell Therapeutics (LCTX) FCF Margin (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics has reported FCF Margin for 17 years, with the latest figure at 472.35% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 14059.0% year-over-year to 472.35%; the trailing twelve-month figure through Mar 2026 stood at 152.96% (up 8581.0% YoY), and the FY2025 full-year result was 133.56%, up 11549.0% from the prior year.
- FCF Margin for Q1 2026 stood at 472.35%, down from 81.34% in the prior quarter.
- The five-year high for FCF Margin was 417.38% in Q1 2022, with the low at 479.04% in Q1 2023.
- Historically, FCF Margin has averaged 238.87% across 5 years, with a median of 234.0% in 2024.
- Annual changes were most pronounced in 2022 — FCF Margin soared 231891 bps — and 2023, when it tumbled 89642 bps.
- Lineage Cell Therapeutics' FCF Margin stood at 412.64% in 2022, then increased by 22 bps to 320.16% in 2023, then grew by 27 bps to 234.0% in 2024, then jumped by 65 bps to 81.34% in 2025, then sank by 481 bps to 472.35% in 2026.
- The last three FCF Margin figures came in at 472.35% (Q1 2026), 81.34% (Q4 2025), and 95.9% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | -472.35% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -472.35% |
| Dec 31, 2025 | -81.34% |
| Sep 30, 2025 | -95.90% |
| Jun 30, 2025 | -200.83% |
| Mar 31, 2025 | -331.76% |
| Dec 31, 2024 | -234.00% |
| Sep 30, 2024 | -156.89% |
| Jun 30, 2024 | -369.03% |
| Mar 31, 2024 | -403.12% |
| Dec 31, 2023 | -320.16% |
| Sep 30, 2023 | -369.26% |
| Jun 30, 2023 | -202.29% |
| Mar 31, 2023 | -479.04% |
| Dec 31, 2022 | -412.64% |
| Sep 30, 2022 | -192.33% |
| Jun 30, 2022 | -157.24% |
| Mar 31, 2022 | 417.38% |
| Dec 31, 2021 | -12.04% |
| Sep 30, 2021 | -215.95% |
| Jun 30, 2021 | -1,083.01% |